

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Peggy E. Hellberg

Serial No.: 10/531,747 (Conf. #3474)

Filed: April 18, 2005

For: Histone Deacetylase Inhibitors for Treating
Degenerative Diseases of the Eye

Group Art Unit: 1612

Examiner: Huang, G.

Atty. Dkt. No.: 2395 US F

RESPONSE TO RESTRICTION REQUIREMENT
DATED MAY 29, 2008

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Responsive to the Restriction Requirement mailed May 29, 2008, Applicants elect glaucoma as the species to which the claims should be restricted if no generic claim is finally held to be allowable. Claims 1, 2, and 4 are readable on the elected species. No fees are believed to be due with this response. However, the Commissioner is authorized to charge any fees that may be due under 37 CFR §§1.16 to 1.21 to Alcon Laboratories Deposit Account No. 501051. The Examiner is invited to contact the undersigned attorney as indicated below with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,

/Jason J. Derry, #50,692/

Jason J. Derry, Ph.D.
Reg. No. 50,692
Attorney for Applicants

Date: June 30, 2008